Skip to content

DAPA (Defibrillator After Primary Angioplasty) ¡V Randomized Trial.

Implantable Defibrillator early after Primary PCI for ST-Elevation Myocardial Infarction.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28488
Enrollment
700
Registered
2005-08-02
Start date
2004-03-03
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary angioplasty for acute MI within 30-60 days with at least one of the following criteria: 1) TIMI flow after PCI less than 3

Interventions

Sponsors

A.R. Ramdat Misier, MD, PhD, Zwolle, The Netherlands J.P. Ottervanger MD, PhD, Zwolle, The Netherlands Prof. M.J. Schalij MD, PhD, Leiden, The Netherlands Prof. F. Zijlstra MD, PhD, Groningen, The Netherlands E.F.D. Wever MD, PhD, Nieuwegein, The Netherlands M.J. de Boer, MD, PhD (Zwolle, The Netherlands) W. Beukema, MD (Zwolle, The Netherlands) L. van Erven, MD, PhD (Leiden, The Netherlands) I.C. van Gelder, MD, PhD (Groningen, The Netherlands)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ST-elevation myocardial infarction treated with primary PCI within 30 days and 60 days before randomisation2.At least one of the following criteria: 1. TIMI flow after primary PCI less than 3 in the infarct related vessel; 2. Left ventricular ejection lower than 30% as measured within 4 days after admission.

Exclusion criteria

Exclusion criteria: 1. Class I indication for ICD implantation; 2. Documented previous myocardial infarction with LVEF < 30%; 3. Age < 18 years; 4. Heart failure with New York Heart Association functional class IV; 5. Inotropic medication within 2 weeks before randomisation; 6. Mechanical tricuspid valve; 7. Serious comorbidity such as cancer, with a high likelihood of death during the trial; 8. Advanced cerebrovascular disease; 9. Unwilling or unable to sign the consent form for participation; 10. Females of childbearing age not using medically prescribed contraceptives.

Design outcomes

Primary

MeasureTime frame
The primary endpoint of the study is all-cause mortality.

Secondary

MeasureTime frame
Secondary endpoints are the incidence of sudden cardiac death and sustained ventricular tachycardia (VT). Sudden cardiac death is defined as occurring within 1 hour of the onset of symptoms or, if death is not witnessed, during sleep or within 24 hours of last occasion on which the patient was seen in a healthy state.

Contacts

Public ContactJ. Klijn

Diagram B.V. Zwolle Dokter Stolteweg 96

j.klijn@diagram-zwolle.nl+31 (0)38 4262997

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)